How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists
about
Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancerDecentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis testNew Robust and Reproducible Stereological IHC Ki67 Breast Cancer Proliferative Assessment to Replace Traditional Biased Labeling Index.Tumor tissue protein signatures reflect histological grade of breast cancerAn international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®Current breast cancer proliferative markers correlate variably based on decoupled duration of cell cycle phases.Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling indexA methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissueKi67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancerDeterminants of outcome of solitary fibrous tumors of the pleura: an observational cohort study.Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarraysNew insight into Ki67 expression at the invasive front in breast cancer.Mitotic Index is an Independent Predictor of Recurrence-Free Survival in Meningioma.High tumor budding stratifies breast cancer with metastatic properties.Quantum dots-based quantitative and in situ multiple imaging on ki67 and cytokeratin to improve ki67 assessment in breast cancer.Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 studyAn interobserver reproducibility analysis of Ki67 visual assessment in breast cancer.Androgen receptor status is highly conserved during tumor progression of breast cancer.A Comparison of Visual Assessment and Automated Digital Image Analysis of Ki67 Labeling Index in Breast Cancer.Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.Prognostic significance of Ki67 in Chinese women diagnosed with ER+/HER2- breast cancers by the 2015 St. Gallen consensus classification.Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.Quantum dots-based double imaging combined with organic dye imaging to establish an automatic computerized method for cancer Ki67 measurementThe 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.Impact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey.Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up.Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.A simple and reproducible prognostic index in luminal ER-positive breast cancersFrom High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis.Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.Semi-automated evaluation of Ki-67 index in invasive ductal carcinoma of the breast.An international Ki67 reproducibility study.Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.Subtyping of breast cancer using reverse phase protein arrays.Pathologic diagnosis, immunohistochemistry, multigene assays and breast cancer treatment: progress toward "precision" cancer therapy.The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma.Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.Immunohistochemistry should undergo robust validation equivalent to that of molecular diagnostics.Biomarker assessment and molecular testing for prognostication in breast cancer.Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy.
P2860
Q21089802-35074498-FADE-4D5B-9DF8-9B1E49F81D41Q21261272-75E9DD5A-5873-4BE4-A225-C502BF9F738DQ30489246-036733C2-D8B8-406D-8074-3E9283266252Q33365644-9890ADB7-231F-400C-8261-3279C414487EQ33660598-76DF77E1-244A-4BB1-B16D-96E63B8F8E82Q33687123-42B8F263-75CF-4B4B-B683-441A46E9BC1EQ33717341-586592BF-9271-4526-A441-956CDAE08FB8Q33739487-7677B431-E63F-441E-B1C8-87F617A4D7B1Q34012047-8B06CC8D-40CA-40F1-9FD1-ED33C5EA3AECQ34050170-05B376E0-F6EC-42AF-A877-7D03086FB4C3Q34466187-17B26D31-5909-42F5-A173-D282B26DDB72Q34575792-C7D586E0-E96F-4815-97E6-43922BC0A12FQ34980413-243B00B8-C275-4A92-9BB1-3A9B4A0CB0BBQ35203546-650FDAAB-77BC-4836-9907-DFA381D92B49Q35347732-70D4D89B-7D72-4524-9EBA-837609035C06Q35462377-990C24DC-6F0D-4B4B-A241-0620BE1C2603Q35560945-47C10815-F344-4699-BE33-79FC5CA4A8B6Q35836387-913226CC-63A1-4D93-9457-16C330E8C159Q35940233-7CE7FE70-3693-4A97-9D53-48A4F1632A1EQ36070547-CC3FC6F8-8B79-49E2-B992-AC9FE340AC22Q36243382-6A0FC67D-07C2-4B4E-807A-EF695C94B1B8Q36279137-C0B370D8-26F1-4DB1-91F3-AAEFEA0618A6Q36536487-768E080F-B949-403B-AA18-1F6FE037D40DQ36615770-D9C0EAFA-9280-4856-9230-70524C994E0CQ36791866-F89A46DB-9808-49A0-A56D-6B9C6476A9D2Q36922535-96F6316B-0AF3-448F-8A10-6403F8F92B9FQ36994974-00CF4A6B-4725-42A8-9415-94DF42FBA12DQ37126908-DDC9AC79-B69D-4657-99B2-A083C3A9EB8AQ37214217-3F4AADAB-C689-461E-ACAA-FF2335122F9DQ37383276-5B7D39A3-E8CC-443B-B640-AE378EC75D4DQ37388652-E01F65B4-B1CE-46E2-B40D-3AE5E2FB6A08Q37463125-775B0419-367C-470B-BEE3-DECEE190A51AQ38232507-755A112B-B914-4EC3-9717-0A458D645690Q38268585-DF3A7AA4-9035-4FB6-ABE7-BF49289E357EQ38272730-E4689984-AC9C-4046-A00F-C08AE9CF93FBQ38302260-CA1E7572-CDF7-4991-9EE5-AB12D486B12FQ38374747-D3F7A25D-6774-48B3-A968-1C34712129DCQ38568269-A0CE9236-7C68-4C0C-AD04-2EE047711424Q38696790-49156E91-87D4-46D1-A756-C3288AD70ED2Q39187437-823552A8-B857-48E3-8536-4D895D2A4971
P2860
How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
How reliable is Ki-67 immunohi ...... Breast- and Gynecopathologists
@ast
How reliable is Ki-67 immunohi ...... Breast- and Gynecopathologists
@en
How reliable is Ki-67 immunohi ...... Breast- and Gynecopathologists
@nl
type
label
How reliable is Ki-67 immunohi ...... Breast- and Gynecopathologists
@ast
How reliable is Ki-67 immunohi ...... Breast- and Gynecopathologists
@en
How reliable is Ki-67 immunohi ...... Breast- and Gynecopathologists
@nl
prefLabel
How reliable is Ki-67 immunohi ...... Breast- and Gynecopathologists
@ast
How reliable is Ki-67 immunohi ...... Breast- and Gynecopathologists
@en
How reliable is Ki-67 immunohi ...... Breast- and Gynecopathologists
@nl
P2093
P2860
P50
P3181
P1433
P1476
How reliable is Ki-67 immunohi ...... Breast- and Gynecopathologists
@en
P2093
Barbara Padberg
Christian Ohlschlegel
Christiane Rakozy
Corina Dommann-Scherrer
Coya Tapia
Daniela Kaup
Ellen Obermann
Gad Singer
Hans-Anton Lehr
Harald Frick
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0037379
P407
P577
2012-01-01T00:00:00Z